Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | WNT3A | P56704 | 3/20 | 0.49 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.49 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.48 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.48 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.48 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.48 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.46 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | CCNC | P24863 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31119862 | 1.00 | DYRK1A (0.62) | DYRK1ALMNAMAPTUHRF1HTT | |
| Hydrochloric Acid SCHEMBL30657718 | 0.98 | DYRK1A (0.60) | DYRK1ALMNAMAPTUHRF1HTT | |
| Iodide SCHEMBL28298350 | 0.98 | DYRK1A (0.60) | DYRK1ALMNAMAPTUHRF1HTT | |
| SCHEMBL30308690 | 0.90 | DYRK1A (0.65) | DYRK1AUHRF1WNT3ANFATC1PSEN1 | |
| SCHEMBL1896511 | 0.90 | DYRK1A (0.65) | DYRK1AUHRF1WNT3ANFATC1PSEN1 | |
| Iodide SCHEMBL9618570 | 0.87 | DYRK1A (0.63) | DYRK1AUHRF1WNT3ANFATC1PSEN1 | |
| SCHEMBL134658 | 0.84 | DYRK1A (0.60) | DYRK1AUHRF1WNT3APSEN1PSEN2 | |
| SCHEMBL30559511 | 0.84 | DYRK1A (0.60) | DYRK1AUHRF1WNT3APSEN1PSEN2 | |
| SCHEMBL6855459 | 0.84 | DYRK1A (0.66) | DYRK1AUHRF1WNT3APSEN1PSEN2 | |
| SCHEMBL18174668 | 0.84 | DYRK1A (0.51) | DYRK1AWNT3ANFATC1PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110387036-A | A kind of random polyarylether electrode active material and preparation method thereof containing purpurine side chain | 福州大学 | 2019-10-29 | — | — | CN | claimed |
| CN-110305313-A | A kind of purpurine functional poly aryl oxide electrode active material and preparation method thereof | 福州大学 | 2019-10-08 | — | — | CN | claimed |
| CN-109796396-A | A kind of preparation method of N- methyl -4,4 '-bipyridyl iodide | 山西医科大学 | 2019-05-24 | — | — | CN | claimed |
| CN-103113876-B | Photochromic optomagnetic material | 中国科学院福建物质结构研究所 | 2017-02-08 | — | — | CN | claimed |
| CN-103113876-A | Photochromic optomagnetic material | FUJIAN MATTER STRUCTURE | 2013-05-22 | — | — | CN | claimed |
| US-20250122402-A1 | LONG SHELF-LIFE STABLE MASS POLYMERIZABLE POLYCYCLOOLEFIN COMPOSITIONS CONTAINING PYRIDINE LIGATED PALLADIUM COMPOUNDS | PROMERUS, LLC (US) | 2025-04-17 | — | — | US | disclosed |
| US-12162895-B2 | DNA polymerase theta inhibitor for treatment of cancer | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-12-10 | — | — | US | disclosed |
| US-12145945-B2 | Compounds, compositions, and therapeutic uses thereof | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-11-19 | — | — | US | disclosed |
| US-20240336628-A1 | NOVEL COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-10-10 | — | — | US | disclosed |
| US-20240327431-A1 | DNA POLYMERASE THETA INHIBITOR FOR TREATMENT OF CANCER | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-10-03 | — | — | US | disclosed |
| US-20240327430-A1 | NOVEL COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-10-03 | — | — | US | disclosed |
| US-11818932-B2 | Organic light-emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-11-14 | — | — | US | disclosed |
| WO-2010107244-A2 | NOVEL ORGANIC ELECTROLUMINESCENT COMPOUNDS AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | DOW ADVANCED DISPLAY MATERIALS, LTD. (KR) | 2010-09-23 | — | — | WO | disclosed |
| US-20090281311-A1 | 1,3,5-TRIAZINE DERIVATIVE, PRODUCTION METHOD THEREOF AND ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THIS AS A COMPOSING COMPONENT | TOSOH CORPORATION (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281311-A1 | 1,3,5-TRIAZINE DERIVATIVE, PRODUCTION METHOD THEREOF AND ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THIS AS A COMPOSING COMPONENT | TOSOH CORPORATION (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090066223-A1 | ORGANIC ELECTRIC FIELD LIGHT EMITTING ELEMENT AND PRODUCTION THEREFOR | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20090066223-A1 | ORGANIC ELECTRIC FIELD LIGHT EMITTING ELEMENT AND PRODUCTION THEREFOR | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-03-12 | — | — | US | disclosed |
| EP-1857521-A1 | ORGANIC ELECTRIC FIELD LIGHT EMITTING ELEMENT AND PRODUCTION THEREFOR | Mitsubishi Chemical Corporation (JP) | 2007-11-21 | — | — | EP | disclosed |
| US-5516462-A | VIOLOGEN COMPOUND; POTASSIUM SALT ELECTROLYTE AND SOLVENT MIXTURES; REVERSIBLE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1996-05-14 | — | — | US | disclosed |
| CN-88100754-A | The Aquo-composition of cation compound and xanthene glue | — | 1988-09-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162895-B2 | DNA polymerase theta inhibitor for treatment of cancer | POLQ, POLB, POLH | DYRK1A 3264/4885LMNA 1602/4885MAPT 1209/4885 |
| US-20240327430-A1 | NOVEL COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF | POLQ, POLK, POLB | DYRK1A 4125/4885LMNA 1558/4885MAPT 1489/4885 |
| US-20240336628-A1 | NOVEL COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF | POLQ, POLK, POLB | DYRK1A 4125/4885LMNA 1558/4885MAPT 1489/4885 |
| US-20240327431-A1 | DNA POLYMERASE THETA INHIBITOR FOR TREATMENT OF CANCER | POLQ, POLB, POLH | DYRK1A 3264/4885LMNA 1602/4885MAPT 1209/4885 |
| US-12145945-B2 | Compounds, compositions, and therapeutic uses thereof | POLQ, POLK, POLB | DYRK1A 4090/4885LMNA 1116/4885MAPT 1441/4885 |
| US-20090281311-A1 | 1,3,5-TRIAZINE DERIVATIVE, PRODUCTION METHOD THEREOF AND ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THIS AS A COMPOSING COMPONENT | KCNJ2, KCNA4, KCNJ4 | DYRK1A 3920/4885LMNA 4422/4885MAPT 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.